Speech-Language Pathologists in Wamego, KS Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Paula Shelley, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 301 Walnut St, Wamego, KS 66547 Phone: 785-458-9472 |
Joleen Eisele Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 303 Ruths Ln, Wamego, KS 66547 Phone: 785-456-7940 |
Ms. Theresa F Pettay, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 21105 School View Rd, Wamego, KS 66547 Phone: 785-456-7326 |
Sara Mccarthy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1311 14th St, Wamego, KS 66547 Phone: 785-272-1535 |
News Archive
Angion Biomedica initiates BB3 Phase II trial in heart attack
Angion Biomedica Corp. announced today that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction).
Stereotypes and misinformation about HIV still commonplace in healthcare
The doctor who wouldn't come into the patient's hospital room. The neurologist who avoided eye contact. The ambulance attendant who angrily threw her bloodied gloves into the street after learning the injured patient was HIV-positive.
TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer
The Translational Genomics Research Institute (TGen) and Scottsdale Healthcare are testing a new drug specifically for thymic cancer based on early promising results at Scottsdale Healthcare.
Institute of Materia Medica and TB Alliance partner to tackle tuberculosis
The Institute of Materia Medica (IMM), a member of the Chinese Academy of Medical Sciences, and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs, today announced plans to pursue a joint research partnership to develop promising, novel anti-tuberculosis agents.
ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA
ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera's aura6000 hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea. The target population for ImThera's neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure.
› Verified 3 days ago
Optometrists
Chiropractors
Physical Therapists
Speech-Language Pathologists
Occupational Therapists